Current and emerging therapies for the treatment of myasthenia gravis

@inproceedings{Mantegazza2011CurrentAE,
  title={Current and emerging therapies for the treatment of myasthenia gravis},
  author={Renato Mantegazza and Silvia Bonanno and Giorgia Camera and Carlo Giuseppe Antozzi},
  booktitle={Neuropsychiatric disease and treatment},
  year={2011}
}
Myasthenia gravis (MG) is an autoimmmune disease in which autoantibodies to different antigens of the neuromuscular junction cause the typical weakness and fatigability. Treatment includes anticholinesterase drugs, immunosuppression, immunomodulation, and thymectomy. The autoimmune response is maintained under control by corticosteroids frequently associated with immunosuppressive drugs, with improvement in the majority of patients. In case of acute exacerbations with bulbar symptoms or… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 21 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 83 references

Guidelines for the treatment of autoimmune neuromuscular transmission disorders.

European journal of neurology • 2006
View 9 Excerpts
Highly Influenced

Unravelling the pathogenesis of myasthenia gravis

Nature Reviews Immunology • 2002
View 11 Excerpts
Highly Influenced

Intravenous immunoglobulin for myasthenia gravis.

The Cochrane database of systematic reviews • 2012
View 1 Excerpt

The value of thymectomy in myasthenia gravis: a computer-assisted matched study

JM Buckingham, FM JrHoward, PE Bernatz
Ann Surg. 1976;184:453–458 • 2011
View 1 Excerpt

Similar Papers

Loading similar papers…